Gene editing is good because it solves problems that were previously unsolvable, from curing genetic diseases with a single treatment to growing crops that survive drought. The technology allows scientists to make precise changes to DNA the way you might fix a typo in a document, and it’s already producing real results in medicine, agriculture, and public health.
Curing Genetic Diseases in One Treatment
The most dramatic benefit of gene editing is its potential to cure diseases that previously required lifelong management. Sickle cell disease is the clearest example. People with sickle cell produce misshapen red blood cells that clump together, causing episodes of severe pain called vaso-occlusive crises. These episodes can strike multiple times a year, often requiring hospitalization.
In December 2023, the FDA approved Casgevy, the first gene editing therapy for sickle cell disease. The treatment works by editing a patient’s own blood stem cells, then returning them to the body. In clinical trials, 29 out of 31 patients (93.5%) were completely free of severe pain episodes for at least 12 consecutive months. A second gene therapy called Lyfgenia showed similar results, with 88% of patients achieving complete resolution of pain crises. For a disease that has no conventional cure and affects roughly 100,000 Americans, those numbers represent a fundamental shift in what’s possible.
Older gene therapies worked by inserting a new copy of a gene using a virus as a delivery vehicle. That approach helps with conditions caused by a missing gene, but it can’t fix the underlying mutation, and it doesn’t work well for diseases caused by a dominant faulty gene. Gene editing is different because it corrects or disables the specific piece of DNA causing the problem. It treats the root cause rather than adding a workaround.
Feeding More People With Less Water
Climate change is making droughts more frequent and more severe, threatening staple crops in regions that can least afford it. Gene editing offers a way to make crops more resilient without the lengthy breeding programs that can take decades. In maize, researchers used CRISPR to create new variants of a gene called ARGOS8 that regulates how the plant responds to stress. The edited maize lines produced significantly more grain during drought conditions in field trials, with minimal yield reduction during normal growing seasons. That’s a rare win-win: better performance under stress without sacrificing anything when conditions are good.
Similar work is happening in rice, the dietary staple for roughly half the world’s population. Researchers have identified and edited multiple genes involved in drought tolerance, producing rice varieties that maintain higher grain filling under water stress. Other edits have improved rice’s ability to handle oxidative damage during dry periods. Because these changes involve tweaking genes the plant already has rather than inserting foreign DNA, many countries regulate gene-edited crops differently from traditional GMOs, which could speed up adoption.
Making Staple Foods More Nutritious
Malnutrition isn’t just about calories. Hundreds of millions of people eat enough food but don’t get enough essential vitamins and minerals, a problem sometimes called “hidden hunger.” Gene editing can boost the nutritional content of crops people already eat. Golden rice, developed using CRISPR to insert genes involved in producing beta-carotene (the precursor to vitamin A), contains 7.9 micrograms per gram of beta-carotene in the edible grain. Vitamin A deficiency affects an estimated 250 million preschool children worldwide and is a leading cause of preventable blindness.
Beyond vitamins, CRISPR has been used to increase beneficial compounds like GABA in tomatoes, improve protein content in grains, and boost levels of healthy fatty acids in oilseed crops. These changes can be made to local varieties that farmers already grow, rather than requiring them to adopt entirely new crop types.
Fighting Malaria at the Genetic Level
Malaria kills more than 600,000 people each year, mostly children in sub-Saharan Africa. Bed nets and insecticides help, but mosquitoes evolve resistance. Gene drives, a technology built on CRISPR, offer a radically different approach: editing wild mosquito populations so they can no longer transmit the parasite or reproduce effectively.
In laboratory studies, researchers have placed CRISPR-based gene drives at specific locations in mosquito DNA that render female mosquitoes infertile, achieving close to 100% inheritance rates. That means nearly every offspring carries the edit, allowing it to spread rapidly through a population. Real-world implementation is still being tested carefully, and early results show the drives can reach high frequency within just a few generations. The technology wouldn’t eliminate mosquitoes entirely but could suppress populations of the specific species that carry malaria below the threshold needed for transmission.
Making Organ Transplants Possible
More than 100,000 Americans are on the organ transplant waiting list at any given time, and thousands die each year waiting. Gene editing has opened a path toward using pig organs in human patients, something that was previously impossible because the human immune system immediately attacks pig tissue.
At NYU Langone Health, the first clinical trial of a gene-edited pig kidney transplant is underway. The pig kidneys carry 10 separate gene edits: four pig genes are knocked out to reduce the risk of rejection and control organ growth, while six human genes are added to help the recipient’s body accept the organ. This kind of precise, multi-gene engineering simply wasn’t feasible before CRISPR.
Precision That Keeps Improving
One early concern about gene editing was accuracy. The original CRISPR system occasionally cut DNA at the wrong location, creating unintended mutations called off-target effects. That concern was valid, but the technology has improved rapidly. Newer high-fidelity versions of the CRISPR enzyme reduce off-target edits by 94% to 98.7% compared to the original system. One refined version called evoCas9 cut unintended sites by 98.7% in direct comparisons. For context, one guide sequence targeting a specific gene produced 134 off-target cuts with the original enzyme but only 18 to 24 with the improved versions.
This level of precision matters because it makes gene editing safe enough for therapeutic use in humans, where even a small number of unintended mutations could theoretically cause problems. The trend line is clear: each generation of the technology gets more accurate, expanding the range of conditions and applications where the benefits outweigh the risks.
Why It Matters Beyond Individual Applications
What makes gene editing genuinely transformative, rather than just another useful tool, is its versatility and accessibility. The same core technology that cures sickle cell disease also makes drought-resistant corn, nutritious rice, and transplantable pig organs. CRISPR is relatively inexpensive and simple compared to older genetic engineering methods, which means labs in lower-income countries can use it too. A university research team can now do work that would have required a major pharmaceutical company’s budget 15 years ago.
The practical impact compounds over time. A single gene-edited crop variety, once developed, can be grown by millions of farmers indefinitely. A one-time gene editing treatment for sickle cell disease replaces decades of pain management, blood transfusions, and hospital visits. A successful gene drive could reduce malaria transmission across an entire continent. These aren’t incremental improvements. They represent permanent solutions to problems that have resisted every other approach.